 David Badesch
Concepts (502)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 106 | 2023 | 1794 | 6.990 |
Why?
| | Antihypertensive Agents | 31 | 2019 | 437 | 3.200 |
Why?
| | Epoprostenol | 23 | 2015 | 132 | 2.100 |
Why?
| | Vasodilator Agents | 12 | 2015 | 328 | 1.280 |
Why?
| | Registries | 20 | 2022 | 1810 | 1.180 |
Why?
| | Familial Primary Pulmonary Hypertension | 16 | 2023 | 193 | 1.070 |
Why?
| | Piperazines | 8 | 2014 | 316 | 1.040 |
Why?
| | Sulfones | 7 | 2012 | 98 | 1.020 |
Why?
| | Pulmonary Wedge Pressure | 8 | 2020 | 65 | 1.010 |
Why?
| | Hemodynamics | 28 | 2023 | 1003 | 0.940 |
Why?
| | Exercise Tolerance | 19 | 2023 | 233 | 0.920 |
Why?
| | Vascular Resistance | 9 | 2023 | 356 | 0.910 |
Why?
| | Scleroderma, Systemic | 6 | 2021 | 94 | 0.850 |
Why?
| | Connective Tissue Diseases | 5 | 2018 | 57 | 0.850 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1440 | 0.820 |
Why?
| | Sulfonamides | 12 | 2018 | 445 | 0.790 |
Why?
| | Exercise Test | 11 | 2020 | 551 | 0.750 |
Why?
| | Phenylpropionates | 5 | 2011 | 17 | 0.730 |
Why?
| | Respiratory System Agents | 2 | 2023 | 22 | 0.720 |
Why?
| | Pulmonary Artery | 14 | 2023 | 1063 | 0.680 |
Why?
| | Natriuretic Peptide, Brain | 9 | 2021 | 106 | 0.660 |
Why?
| | Pyridazines | 5 | 2011 | 50 | 0.660 |
Why?
| | Double-Blind Method | 21 | 2023 | 1687 | 0.610 |
Why?
| | Adult | 70 | 2023 | 31512 | 0.590 |
Why?
| | Endothelin Receptor Antagonists | 9 | 2015 | 59 | 0.580 |
Why?
| | Humans | 135 | 2023 | 118972 | 0.580 |
Why?
| | Middle Aged | 71 | 2022 | 27617 | 0.530 |
Why?
| | Disease Management | 6 | 2016 | 571 | 0.480 |
Why?
| | Lung Transplantation | 9 | 2002 | 263 | 0.470 |
Why?
| | Thrombosis | 1 | 2016 | 309 | 0.440 |
Why?
| | Anticoagulants | 3 | 2016 | 559 | 0.440 |
Why?
| | Cardiac Catheterization | 12 | 2023 | 541 | 0.440 |
Why?
| | Anemia, Sickle Cell | 5 | 2014 | 230 | 0.440 |
Why?
| | Male | 83 | 2022 | 57801 | 0.430 |
Why?
| | Female | 80 | 2022 | 61564 | 0.420 |
Why?
| | Consensus | 1 | 2014 | 534 | 0.420 |
Why?
| | Risk Assessment | 13 | 2021 | 3057 | 0.410 |
Why?
| | Prognosis | 16 | 2021 | 3443 | 0.410 |
Why?
| | Treatment Outcome | 26 | 2023 | 9342 | 0.390 |
Why?
| | Recombinant Fusion Proteins | 3 | 2023 | 653 | 0.390 |
Why?
| | Aged | 37 | 2021 | 19657 | 0.380 |
Why?
| | Survival Rate | 15 | 2022 | 1720 | 0.380 |
Why?
| | Prostaglandins | 3 | 2007 | 78 | 0.380 |
Why?
| | Thinness | 1 | 2011 | 91 | 0.380 |
Why?
| | Activities of Daily Living | 3 | 2016 | 354 | 0.350 |
Why?
| | Oxygen Consumption | 1 | 2012 | 586 | 0.350 |
Why?
| | Blood Pressure | 8 | 2014 | 1664 | 0.350 |
Why?
| | Hypertension, Portal | 4 | 2011 | 67 | 0.340 |
Why?
| | Pyrimidines | 3 | 2018 | 382 | 0.340 |
Why?
| | Sildenafil Citrate | 8 | 2014 | 57 | 0.330 |
Why?
| | Coagulants | 1 | 2008 | 12 | 0.330 |
Why?
| | Factor VIIa | 1 | 2008 | 36 | 0.320 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2220 | 0.320 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4708 | 0.320 |
Why?
| | Purines | 8 | 2014 | 161 | 0.300 |
Why?
| | Depressive Disorder | 1 | 2010 | 333 | 0.300 |
Why?
| | Mixed Connective Tissue Disease | 2 | 2010 | 8 | 0.290 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 693 | 0.290 |
Why?
| | Health Status | 2 | 2016 | 726 | 0.280 |
Why?
| | Prospective Studies | 16 | 2021 | 6471 | 0.280 |
Why?
| | Quality of Life | 10 | 2021 | 2366 | 0.270 |
Why?
| | Hemorrhage | 2 | 2008 | 623 | 0.270 |
Why?
| | Pulmonary Medicine | 3 | 2019 | 85 | 0.260 |
Why?
| | Phosphodiesterase 5 Inhibitors | 3 | 2014 | 36 | 0.260 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2021 | 1945 | 0.240 |
Why?
| | Hospitalization | 6 | 2022 | 1785 | 0.240 |
Why?
| | Castleman Disease | 1 | 2003 | 14 | 0.240 |
Why?
| | Follow-Up Studies | 15 | 2018 | 4596 | 0.240 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1137 | 0.230 |
Why?
| | Adolescent | 22 | 2021 | 18480 | 0.230 |
Why?
| | DEAE-Dextran | 1 | 2023 | 1 | 0.230 |
Why?
| | Herpesvirus 8, Human | 1 | 2003 | 68 | 0.230 |
Why?
| | Body Mass Index | 1 | 2011 | 2092 | 0.230 |
Why?
| | United States | 20 | 2022 | 12555 | 0.220 |
Why?
| | Biomarkers | 6 | 2021 | 3588 | 0.220 |
Why?
| | Muscle, Smooth, Vascular | 6 | 1994 | 454 | 0.220 |
Why?
| | Ventricular Function, Right | 5 | 2009 | 257 | 0.210 |
Why?
| | Phosphodiesterase Inhibitors | 4 | 2009 | 86 | 0.210 |
Why?
| | Herpesviridae Infections | 1 | 2003 | 142 | 0.210 |
Why?
| | Pyrazoles | 2 | 2015 | 363 | 0.210 |
Why?
| | Lung | 7 | 2019 | 3664 | 0.200 |
Why?
| | Insulin-Like Growth Factor I | 4 | 1994 | 287 | 0.200 |
Why?
| | Fluid Shifts | 1 | 2020 | 1 | 0.190 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 59 | 0.190 |
Why?
| | Walking | 8 | 2014 | 415 | 0.190 |
Why?
| | Methamphetamine | 1 | 2021 | 51 | 0.190 |
Why?
| | Drug Therapy, Combination | 6 | 2014 | 965 | 0.190 |
Why?
| | Rituximab | 1 | 2021 | 155 | 0.190 |
Why?
| | Echocardiography | 4 | 2020 | 556 | 0.190 |
Why?
| | Infusions, Intravenous | 7 | 2009 | 380 | 0.190 |
Why?
| | Heart | 2 | 2023 | 631 | 0.180 |
Why?
| | Vasculitis | 2 | 1998 | 75 | 0.180 |
Why?
| | Somatomedins | 2 | 1990 | 27 | 0.180 |
Why?
| | Disease Progression | 5 | 2015 | 2490 | 0.180 |
Why?
| | Sodium Chloride | 1 | 2020 | 144 | 0.180 |
Why?
| | Thorax | 1 | 2019 | 45 | 0.170 |
Why?
| | Young Adult | 10 | 2021 | 10793 | 0.170 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2019 | 5 | 0.170 |
Why?
| | Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.170 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.170 |
Why?
| | Immunologic Factors | 1 | 2021 | 225 | 0.170 |
Why?
| | SOXF Transcription Factors | 1 | 2018 | 18 | 0.170 |
Why?
| | Isoxazoles | 3 | 2008 | 56 | 0.170 |
Why?
| | Thiophenes | 3 | 2008 | 106 | 0.160 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 78 | 0.160 |
Why?
| | Administration, Oral | 9 | 2015 | 756 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 462 | 0.160 |
Why?
| | Algorithms | 5 | 2019 | 1541 | 0.160 |
Why?
| | Peptide Fragments | 4 | 2021 | 702 | 0.160 |
Why?
| | Time Factors | 14 | 2018 | 6412 | 0.160 |
Why?
| | Liver Diseases | 3 | 2011 | 282 | 0.160 |
Why?
| | Blood Coagulation | 2 | 2016 | 219 | 0.160 |
Why?
| | Obesity | 1 | 2011 | 2746 | 0.160 |
Why?
| | Severity of Illness Index | 9 | 2014 | 2674 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2019 | 187 | 0.150 |
Why?
| | Psychometrics | 2 | 2018 | 631 | 0.150 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2018 | 124 | 0.150 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1125 | 0.140 |
Why?
| | Comorbidity | 5 | 2019 | 1527 | 0.140 |
Why?
| | Pyridines | 2 | 2015 | 440 | 0.140 |
Why?
| | B-Lymphocytes | 1 | 2021 | 770 | 0.140 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 294 | 0.140 |
Why?
| | Iloprost | 2 | 2006 | 46 | 0.130 |
Why?
| | Cohort Studies | 7 | 2020 | 5116 | 0.130 |
Why?
| | Tetrazoles | 1 | 2015 | 32 | 0.130 |
Why?
| | Hemolysis | 2 | 2014 | 174 | 0.130 |
Why?
| | Pulmonary Edema | 1 | 1995 | 125 | 0.130 |
Why?
| | Graft Rejection | 1 | 1998 | 555 | 0.120 |
Why?
| | Pilot Projects | 4 | 2010 | 1419 | 0.120 |
Why?
| | Survival Analysis | 8 | 2018 | 1267 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 734 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 252 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2018 | 3171 | 0.120 |
Why?
| | Delphi Technique | 1 | 2014 | 164 | 0.120 |
Why?
| | Antibodies, Antinuclear | 1 | 1993 | 55 | 0.120 |
Why?
| | Acute Disease | 3 | 2008 | 940 | 0.120 |
Why?
| | Societies, Medical | 2 | 2015 | 703 | 0.120 |
Why?
| | Echocardiography, Doppler | 2 | 2014 | 95 | 0.110 |
Why?
| | Colorado | 3 | 2022 | 4196 | 0.110 |
Why?
| | Models, Theoretical | 2 | 2015 | 556 | 0.110 |
Why?
| | Hypothyroidism | 1 | 1993 | 68 | 0.110 |
Why?
| | Respiratory Function Tests | 5 | 2018 | 526 | 0.110 |
Why?
| | Protein Kinase C | 2 | 1994 | 297 | 0.110 |
Why?
| | Incidence | 5 | 2015 | 2424 | 0.110 |
Why?
| | Endpoint Determination | 2 | 2010 | 69 | 0.110 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 1995 | 240 | 0.110 |
Why?
| | Walk Test | 2 | 2023 | 49 | 0.100 |
Why?
| | Injections, Subcutaneous | 2 | 2023 | 138 | 0.100 |
Why?
| | Risk Factors | 9 | 2018 | 9000 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1244 | 0.100 |
Why?
| | Pulmonary Circulation | 3 | 2018 | 424 | 0.100 |
Why?
| | Survival | 1 | 2011 | 39 | 0.100 |
Why?
| | United Kingdom | 3 | 2021 | 236 | 0.100 |
Why?
| | Prevalence | 4 | 2010 | 2326 | 0.100 |
Why?
| | Respiration, Artificial | 1 | 1995 | 545 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1384 | 0.100 |
Why?
| | Peptidyl-Dipeptidase A | 3 | 2003 | 56 | 0.100 |
Why?
| | Long-Term Care | 1 | 2011 | 74 | 0.100 |
Why?
| | Pain | 2 | 2011 | 735 | 0.100 |
Why?
| | Michigan | 1 | 2010 | 95 | 0.090 |
Why?
| | Reference Values | 2 | 2009 | 774 | 0.090 |
Why?
| | Animals, Newborn | 5 | 1994 | 806 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2018 | 523 | 0.090 |
Why?
| | Endothelin-1 | 2 | 2002 | 168 | 0.090 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 384 | 0.090 |
Why?
| | Aldosterone | 1 | 2009 | 43 | 0.090 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6561 | 0.090 |
Why?
| | Dinoprostone | 1 | 1989 | 193 | 0.090 |
Why?
| | Exercise | 2 | 2018 | 1657 | 0.090 |
Why?
| | Elastin | 1 | 1989 | 77 | 0.080 |
Why?
| | Pulmonary Eosinophilia | 1 | 1989 | 25 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 64 | 0.080 |
Why?
| | Transaminases | 1 | 2008 | 26 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 122 | 0.080 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 73 | 0.080 |
Why?
| | Renal Insufficiency | 1 | 2010 | 150 | 0.080 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 1989 | 83 | 0.080 |
Why?
| | Heart Failure | 2 | 2020 | 1969 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2004 | 402 | 0.080 |
Why?
| | Hospitals, University | 1 | 2008 | 172 | 0.080 |
Why?
| | Lung Diseases | 2 | 2010 | 718 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2023 | 12978 | 0.080 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 374 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2010 | 227 | 0.080 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2009 | 228 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1474 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2018 | 842 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 2275 | 0.080 |
Why?
| | Drug Costs | 1 | 2008 | 94 | 0.080 |
Why?
| | Autoimmune Diseases | 2 | 2005 | 398 | 0.080 |
Why?
| | Drug Utilization | 1 | 2008 | 169 | 0.080 |
Why?
| | Endothelins | 1 | 2007 | 62 | 0.070 |
Why?
| | Depressive Disorder, Major | 1 | 2010 | 303 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2009 | 168 | 0.070 |
Why?
| | Educational Measurement | 1 | 1989 | 289 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 969 | 0.070 |
Why?
| | Hypophosphatemia | 1 | 2006 | 21 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2007 | 117 | 0.070 |
Why?
| | Hypokalemia | 1 | 2006 | 31 | 0.070 |
Why?
| | Appetite Depressants | 1 | 2006 | 21 | 0.070 |
Why?
| | Phosphorus | 1 | 2006 | 84 | 0.070 |
Why?
| | Potassium | 1 | 2006 | 132 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 17 | 0.070 |
Why?
| | Ventricular Function | 1 | 2006 | 60 | 0.070 |
Why?
| | CREST Syndrome | 2 | 2002 | 6 | 0.070 |
Why?
| | Medical Informatics | 1 | 2006 | 102 | 0.070 |
Why?
| | Child | 6 | 2011 | 19129 | 0.070 |
Why?
| | Pleural Diseases | 1 | 2005 | 21 | 0.070 |
Why?
| | Cattle | 5 | 1994 | 978 | 0.070 |
Why?
| | Probability | 3 | 2015 | 305 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2016 | 1868 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 3 | 2010 | 989 | 0.070 |
Why?
| | Analysis of Variance | 3 | 2009 | 1293 | 0.060 |
Why?
| | Forecasting | 3 | 2021 | 353 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2010 | 648 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2005 | 1691 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1308 | 0.060 |
Why?
| | Carbon Monoxide | 2 | 2018 | 64 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2005 | 211 | 0.060 |
Why?
| | Heart Defects, Congenital | 2 | 2009 | 703 | 0.060 |
Why?
| | Age Distribution | 3 | 2010 | 362 | 0.060 |
Why?
| | Sex Distribution | 3 | 2010 | 351 | 0.060 |
Why?
| | Physicians, Family | 1 | 2005 | 206 | 0.060 |
Why?
| | Physician's Role | 1 | 2005 | 200 | 0.060 |
Why?
| | Hypoxia | 3 | 2018 | 963 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 544 | 0.060 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 461 | 0.060 |
Why?
| | Scleroderma, Localized | 1 | 2002 | 6 | 0.060 |
Why?
| | Polymyositis | 1 | 2002 | 14 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2003 | 403 | 0.060 |
Why?
| | Dermatomyositis | 1 | 2002 | 22 | 0.060 |
Why?
| | Serotonin Antagonists | 1 | 2002 | 31 | 0.060 |
Why?
| | Thromboxane-A Synthase | 1 | 2002 | 2 | 0.050 |
Why?
| | Clinical Competence | 1 | 1989 | 951 | 0.050 |
Why?
| | Animals | 11 | 2013 | 33381 | 0.050 |
Why?
| | Liver Function Tests | 3 | 2011 | 107 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2003 | 1012 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 827 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2008 | 736 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2023 | 126 | 0.050 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 16 | 0.050 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 253 | 0.050 |
Why?
| | Biomarkers, Pharmacological | 1 | 2021 | 26 | 0.050 |
Why?
| | Tricuspid Valve Insufficiency | 2 | 2011 | 18 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 207 | 0.050 |
Why?
| | Least-Squares Analysis | 1 | 2021 | 73 | 0.050 |
Why?
| | Injections, Intravenous | 2 | 2013 | 210 | 0.050 |
Why?
| | Tropoelastin | 2 | 1991 | 11 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 2062 | 0.050 |
Why?
| | Reproductive History | 1 | 2020 | 12 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2003 | 455 | 0.050 |
Why?
| | Europe | 2 | 2012 | 356 | 0.050 |
Why?
| | Risk | 2 | 2015 | 853 | 0.050 |
Why?
| | Jaw | 1 | 2000 | 15 | 0.050 |
Why?
| | Infusion Pumps | 1 | 2000 | 32 | 0.050 |
Why?
| | Cells, Cultured | 5 | 1994 | 4077 | 0.050 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 464 | 0.050 |
Why?
| | Cardiac Output | 1 | 2020 | 147 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2874 | 0.050 |
Why?
| | Autoimmunity | 1 | 2005 | 831 | 0.040 |
Why?
| | Internship and Residency | 1 | 1989 | 1001 | 0.040 |
Why?
| | Radiography | 2 | 1995 | 861 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2006 | 867 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 1998 | 415 | 0.040 |
Why?
| | Placebos | 2 | 2011 | 202 | 0.040 |
Why?
| | Genotype | 4 | 2009 | 1882 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 123 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 1999 | 59 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 122 | 0.040 |
Why?
| | Spinal Diseases | 1 | 1999 | 47 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2021 | 185 | 0.040 |
Why?
| | Immunosuppressive Agents | 3 | 1998 | 681 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1999 | 111 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 75 | 0.040 |
Why?
| | Cervical Vertebrae | 1 | 1999 | 115 | 0.040 |
Why?
| | Methicillin Resistance | 1 | 1998 | 19 | 0.040 |
Why?
| | Child, Preschool | 2 | 2011 | 9491 | 0.040 |
Why?
| | Plasmapheresis | 1 | 1998 | 23 | 0.040 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2018 | 58 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2000 | 187 | 0.040 |
Why?
| | Models, Statistical | 1 | 2022 | 636 | 0.040 |
Why?
| | Hemoptysis | 1 | 1998 | 39 | 0.040 |
Why?
| | Bronchiolitis Obliterans | 1 | 1998 | 66 | 0.040 |
Why?
| | Cell Division | 4 | 1994 | 776 | 0.040 |
Why?
| | Capillaries | 1 | 1998 | 103 | 0.040 |
Why?
| | Disease-Free Survival | 2 | 2010 | 649 | 0.040 |
Why?
| | Mass Screening | 2 | 2018 | 1052 | 0.040 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 1998 | 79 | 0.040 |
Why?
| | Biomedical Technology | 1 | 2017 | 43 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1998 | 287 | 0.040 |
Why?
| | Faculty, Medical | 2 | 1990 | 252 | 0.040 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 37 | 0.040 |
Why?
| | Network Meta-Analysis | 1 | 2016 | 15 | 0.040 |
Why?
| | Health Status Indicators | 2 | 2009 | 154 | 0.040 |
Why?
| | Colonic Diseases | 1 | 1996 | 26 | 0.040 |
Why?
| | Intestinal Perforation | 1 | 1996 | 41 | 0.040 |
Why?
| | Uric Acid | 1 | 2000 | 354 | 0.040 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 43 | 0.040 |
Why?
| | Mycoplasma | 1 | 1996 | 7 | 0.040 |
Why?
| | Mycoplasma Infections | 1 | 1996 | 12 | 0.040 |
Why?
| | Translating | 1 | 2016 | 35 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 1997 | 192 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 1997 | 83 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1999 | 344 | 0.030 |
Why?
| | Dyspnea | 2 | 2008 | 201 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2016 | 132 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 1997 | 113 | 0.030 |
Why?
| | Myocardium | 2 | 1998 | 970 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2513 | 0.030 |
Why?
| | Endothelium, Vascular | 2 | 1994 | 907 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 975 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 163 | 0.030 |
Why?
| | Lactobacillus | 1 | 1994 | 23 | 0.030 |
Why?
| | Calibration | 1 | 2015 | 135 | 0.030 |
Why?
| | Fibrinolysis | 1 | 1996 | 159 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 4552 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1994 | 81 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 2 | 1994 | 155 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1998 | 327 | 0.030 |
Why?
| | Drug Approval | 1 | 2015 | 77 | 0.030 |
Why?
| | Antisickling Agents | 1 | 2014 | 5 | 0.030 |
Why?
| | Down Syndrome | 1 | 1999 | 356 | 0.030 |
Why?
| | Focus Groups | 1 | 2016 | 387 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 61 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2014 | 30 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1994 | 154 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 175 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1998 | 346 | 0.030 |
Why?
| | Thyroiditis | 1 | 1993 | 3 | 0.030 |
Why?
| | Raynaud Disease | 1 | 1993 | 6 | 0.030 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 1994 | 67 | 0.030 |
Why?
| | Cytomegalovirus | 1 | 1994 | 144 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 276 | 0.030 |
Why?
| | Genetic Variation | 1 | 2018 | 926 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2014 | 136 | 0.030 |
Why?
| | Research | 2 | 2009 | 411 | 0.030 |
Why?
| | Pneumonia, Bacterial | 1 | 1994 | 110 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 1994 | 195 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 327 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 29 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 183 | 0.030 |
Why?
| | Enzyme Activation | 2 | 1994 | 828 | 0.030 |
Why?
| | Signal Transduction | 3 | 2018 | 4709 | 0.030 |
Why?
| | Creatinine | 1 | 2014 | 491 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 1994 | 187 | 0.030 |
Why?
| | Embolism, Air | 1 | 1992 | 10 | 0.030 |
Why?
| | Erythrocyte Transfusion | 1 | 2014 | 210 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1323 | 0.030 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 62 | 0.030 |
Why?
| | Biomedical Research | 1 | 2017 | 612 | 0.030 |
Why?
| | Preoperative Care | 2 | 2009 | 332 | 0.030 |
Why?
| | Cardiomegaly | 2 | 2006 | 168 | 0.030 |
Why?
| | Qualitative Research | 1 | 2016 | 953 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1636 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 495 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 190 | 0.020 |
Why?
| | Mental Health | 1 | 2016 | 568 | 0.020 |
Why?
| | Mortality | 1 | 2012 | 299 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 364 | 0.020 |
Why?
| | Thromboxane B2 | 1 | 1989 | 27 | 0.020 |
Why?
| | Calcimycin | 1 | 1989 | 57 | 0.020 |
Why?
| | Phenotype | 3 | 2010 | 3003 | 0.020 |
Why?
| | Fellowships and Scholarships | 2 | 1990 | 250 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3457 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 554 | 0.020 |
Why?
| | Drug Synergism | 1 | 1990 | 339 | 0.020 |
Why?
| | Health Policy | 1 | 2012 | 333 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 10 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 22 | 0.020 |
Why?
| | Aromatase | 1 | 2009 | 31 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 34 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 41 | 0.020 |
Why?
| | Dyspepsia | 1 | 2008 | 9 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 394 | 0.020 |
Why?
| | Nitric Oxide | 1 | 1994 | 892 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 46 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1989 | 193 | 0.020 |
Why?
| | California | 1 | 2010 | 382 | 0.020 |
Why?
| | Cognition | 1 | 2016 | 1024 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1989 | 84 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 1998 | 964 | 0.020 |
Why?
| | Vital Capacity | 1 | 2009 | 260 | 0.020 |
Why?
| | Echocardiography, Transesophageal | 1 | 2009 | 89 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1990 | 1094 | 0.020 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 33 | 0.020 |
Why?
| | Vibrio Infections | 1 | 1987 | 2 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2009 | 324 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 126 | 0.020 |
Why?
| | American Heart Association | 1 | 2009 | 270 | 0.020 |
Why?
| | Headache | 1 | 2008 | 128 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 627 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 520 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2009 | 217 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1987 | 37 | 0.020 |
Why?
| | Aminorex | 1 | 2006 | 2 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1989 | 397 | 0.020 |
Why?
| | RNA, Messenger | 2 | 1997 | 2657 | 0.020 |
Why?
| | Heart Rate | 1 | 2010 | 729 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 3 | 2006 | 3174 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 832 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 996 | 0.020 |
Why?
| | Hypoventilation | 1 | 1985 | 7 | 0.020 |
Why?
| | Hepatitis C | 1 | 2008 | 217 | 0.020 |
Why?
| | Estradiol | 1 | 2009 | 476 | 0.020 |
Why?
| | Critical Care | 1 | 1989 | 492 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2005 | 190 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2005 | 185 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 307 | 0.020 |
Why?
| | Magnesium | 1 | 1985 | 150 | 0.020 |
Why?
| | Fibroblasts | 1 | 1989 | 842 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1997 | 2445 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2006 | 248 | 0.020 |
Why?
| | Pancreatic Elastase | 1 | 2004 | 74 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2004 | 48 | 0.020 |
Why?
| | Aging | 1 | 1994 | 1670 | 0.020 |
Why?
| | Hypotension | 1 | 1985 | 120 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1795 | 0.020 |
Why?
| | Potassium Channels | 1 | 2004 | 123 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 1901 | 0.010 |
Why?
| | Tablets | 1 | 2003 | 35 | 0.010 |
Why?
| | DNA | 1 | 1990 | 1388 | 0.010 |
Why?
| | Research Design | 1 | 2009 | 969 | 0.010 |
Why?
| | Arginine | 1 | 2004 | 249 | 0.010 |
Why?
| | Sex Factors | 1 | 2008 | 1781 | 0.010 |
Why?
| | Angiotensin II | 1 | 2003 | 107 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 992 | 0.010 |
Why?
| | Rats | 2 | 2004 | 5392 | 0.010 |
Why?
| | Sepsis | 1 | 1987 | 531 | 0.010 |
Why?
| | Liver Transplantation | 1 | 2009 | 847 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2010 | 1200 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2006 | 727 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 420 | 0.010 |
Why?
| | Colorimetry | 1 | 2000 | 14 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 387 | 0.010 |
Why?
| | Spinal Osteophytosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Spinal Cord Compression | 1 | 1999 | 18 | 0.010 |
Why?
| | Spinal Stenosis | 1 | 1999 | 26 | 0.010 |
Why?
| | Heart Atria | 1 | 2000 | 112 | 0.010 |
Why?
| | Veins | 1 | 1999 | 60 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 311 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 1997 | 35 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 59 | 0.010 |
Why?
| | Heart-Lung Transplantation | 1 | 1997 | 11 | 0.010 |
Why?
| | Arteries | 1 | 1999 | 250 | 0.010 |
Why?
| | Liver Cirrhosis | 1 | 1999 | 245 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 334 | 0.010 |
Why?
| | Diverticulitis, Colonic | 1 | 1996 | 8 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 144 | 0.010 |
Why?
| | Spinal Cord | 1 | 1999 | 367 | 0.010 |
Why?
| | Systole | 1 | 1997 | 168 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1715 | 0.010 |
Why?
| | von Willebrand Factor | 1 | 1996 | 58 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1194 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 183 | 0.010 |
Why?
| | Physical Fitness | 1 | 1997 | 179 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 1999 | 468 | 0.010 |
Why?
| | Proteins | 2 | 1992 | 938 | 0.010 |
Why?
| | Cilazapril | 1 | 1995 | 2 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1995 | 25 | 0.010 |
Why?
| | Tissue Donors | 1 | 1997 | 336 | 0.010 |
Why?
| | Ganciclovir | 1 | 1994 | 46 | 0.010 |
Why?
| | Thymidine | 1 | 1994 | 62 | 0.010 |
Why?
| | Opportunistic Infections | 1 | 1994 | 42 | 0.010 |
Why?
| | Subcellular Fractions | 1 | 1994 | 84 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1999 | 709 | 0.010 |
Why?
| | Lung Diseases, Obstructive | 1 | 1994 | 44 | 0.010 |
Why?
| | Blood | 1 | 1994 | 100 | 0.010 |
Why?
| | Acyclovir | 1 | 1994 | 105 | 0.010 |
Why?
| | Factor VIII | 1 | 1994 | 56 | 0.010 |
Why?
| | Vimentin | 1 | 1994 | 62 | 0.010 |
Why?
| | Viremia | 1 | 1994 | 132 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1816 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1994 | 128 | 0.010 |
Why?
| | Gene Expression | 1 | 1998 | 1489 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 1994 | 200 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1994 | 656 | 0.010 |
Why?
| | Sputum | 1 | 1994 | 290 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 1994 | 287 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 194 | 0.010 |
Why?
| | Lymph | 1 | 1992 | 40 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1994 | 542 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1994 | 1085 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 1991 | 133 | 0.010 |
Why?
| | Financing, Government | 1 | 1990 | 40 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1990 | 115 | 0.010 |
Why?
| | Career Mobility | 1 | 1990 | 66 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2436 | 0.010 |
Why?
| | Research Support as Topic | 1 | 1990 | 114 | 0.010 |
Why?
| | Sheep | 1 | 1992 | 764 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2478 | 0.010 |
Why?
| | Pneumonia, Viral | 1 | 1994 | 348 | 0.010 |
Why?
| | Vibrio | 1 | 1987 | 3 | 0.000 |
Why?
| | Hepatitis, Alcoholic | 1 | 1987 | 13 | 0.000 |
Why?
| | Protein Binding | 1 | 1992 | 1975 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1997 | 2235 | 0.000 |
Why?
| | Citrates | 1 | 1985 | 48 | 0.000 |
Why?
| | RNA | 1 | 1991 | 833 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1995 | 3730 | 0.000 |
Why?
| | Kidney Function Tests | 1 | 1985 | 164 | 0.000 |
Why?
| | Anti-Bacterial Agents | 1 | 1994 | 1510 | 0.000 |
Why?
| | HIV Infections | 1 | 1999 | 2459 | 0.000 |
Why?
| | Infant | 1 | 1994 | 8293 | 0.000 |
Why?
|
|
Badesch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|